HEADER OXYGEN TRANSPORT 29-JAN-97 1ABW TITLE DEOXY RHB1.1 (RECOMBINANT HEMOGLOBIN) COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEMOGLOBIN-BASED BLOOD SUBSTITUTE; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES; COMPND 5 MUTATION: YES; COMPND 6 OTHER_DETAILS: HUMAN HEMOGLOBIN HAS TWO ALPHA CHAINS WHICH ARE CALLED COMPND 7 CHAINS A AND C IN OTHER PDB FILES. IN THIS ENTRY THE TWO ALPHA CHAINS COMPND 8 HAVE BEEN COVALENTLY JOINED TOGETHER BY ONE GLYCINE RESIDUE TO FORM COMPND 9 ONE COVALENTLY LINKED POLYPEPTIDE CHAIN.; COMPND 10 MOL_ID: 2; COMPND 11 MOLECULE: HEMOGLOBIN-BASED BLOOD SUBSTITUTE; COMPND 12 CHAIN: B, D; COMPND 13 ENGINEERED: YES; COMPND 14 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 ORGAN: BLOOD; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 MOL_ID: 2; SOURCE 9 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 10 ORGANISM_COMMON: HUMAN; SOURCE 11 ORGANISM_TAXID: 9606; SOURCE 12 ORGAN: BLOOD; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HEME, OXYGEN TRANSPORT, RESPIRATORY PROTEIN, ERYTHROCYTE EXPDTA X-RAY DIFFRACTION AUTHOR C.E.KUNDROT,K.S.KROEGER REVDAT 4 02-AUG-23 1ABW 1 REMARK SEQADV LINK REVDAT 3 13-JUL-11 1ABW 1 VERSN REVDAT 2 24-FEB-09 1ABW 1 VERSN REVDAT 1 17-JUN-98 1ABW 0 JRNL AUTH K.S.KROEGER,C.E.KUNDROT JRNL TITL STRUCTURES OF A HEMOGLOBIN-BASED BLOOD SUBSTITUTE: INSIGHTS JRNL TITL 2 INTO THE FUNCTION OF ALLOSTERIC PROTEINS. JRNL REF STRUCTURE V. 5 227 1997 JRNL REFN ISSN 0969-2126 JRNL PMID 9032082 JRNL DOI 10.1016/S0969-2126(97)00181-0 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH D.LOOKER,D.ABBOTT-BROWN,P.COZART,S.DURFEE,S.HOFFMAN, REMARK 1 AUTH 2 A.J.MATHEWS,J.MILLER-ROEHRICH,S.SHOEMAKER,S.TRIMBLE,G.FERMI, REMARK 1 AUTH 3 N.H.KOMIYAMA,K.NAGAI,G.L.STETLER REMARK 1 TITL A HUMAN RECOMBINANT HAEMOGLOBIN DESIGNED FOR USE AS A BLOOD REMARK 1 TITL 2 SUBSTITUTE REMARK 1 REF NATURE V. 356 258 1992 REMARK 1 REFN ISSN 0028-0836 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.1 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 5.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 100000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.1000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 86.2 REMARK 3 NUMBER OF REFLECTIONS : 31528 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.164 REMARK 3 FREE R VALUE : 0.232 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.000 REMARK 3 FREE R VALUE TEST SET COUNT : 3141 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.006 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 8 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.09 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 73.30 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2972 REMARK 3 BIN R VALUE (WORKING SET) : 0.2130 REMARK 3 BIN FREE R VALUE : 0.2660 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 0.75 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 337 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.014 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4392 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 206 REMARK 3 SOLVENT ATOMS : 373 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 13.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.014 REMARK 3 BOND ANGLES (DEGREES) : 1.660 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 20.50 REMARK 3 IMPROPER ANGLES (DEGREES) : 2.090 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; 10.000 REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; 10.000 REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; 10.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; 10.000 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO REMARK 3 PARAMETER FILE 2 : PARHCSDX.HEME REMARK 3 PARAMETER FILE 3 : PARAM19.SOL REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : TOPHCSDX.PRO REMARK 3 TOPOLOGY FILE 2 : TOPHCSDX.HEME REMARK 3 TOPOLOGY FILE 3 : TOPH19.SOL REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: A NOTE FROM THE AUTHOR: REMARK 3 CHAINS L AND P MODEL LOW OCCUPANCY STRUCTURES THAT HAVE REMARK 3 THEIR AMINO TERMINUS IN REGISTER WITH VAL A143. REMARK 3 THE SPATIAL ARRANGEMENT OF TWO ALPHA CHAINS OF NORMAL REMARK 3 HEMOGLOBIN CAN BE REPRESENTED SCHEMATICALLY AS REMARK 3 REMARK 3 GHIJ REMARK 3 F A REMARK 3 EDCB REMARK 3 REMARK 3 WHERE FGHIJ IS ONE COVALENT CHAIN AND ABCDE THE OTHER REMARK 3 COVALENT CHAIN. REMARK 3 IN THIS MUTANT HEMOGLOBIN, THERE IS A COVALENT BOND REMARK 3 BETWEEN RESIDUE J AND A, BUT NOT BETWEEN E AND F. REMARK 3 REMARK 3 IN THE CRYSTAL, THE AUTHORS COULD HAVE REMARK 3 REMARK 3 GHIJ BCDE REMARK 3 F A OR A F REMARK 3 EDCB JIHG REMARK 3 REMARK 3 (1) (2) REMARK 3 REMARK 3 THE "F-A" CONTACT WOULD BE LIKE NORMAL HEMOGLOBIN, BUT THE REMARK 3 "E-F" CONTACT HAS A COVALENT LINKAGE THAT BREAKS THE REMARK 3 SYMMETRY. THE ONLY WAY TO TELL IF THE CRYSTAL STRUCTURE REMARK 3 IS (1) OR (2) OR A MIXTURE OF THE TWO IS TO LOOK AT THE REMARK 3 "E-F" AND "J-A" REGIONS. REMARK 3 REMARK 3 IN THIS STRUCTURE, IT COULD BE MOSTLY (1), BUT ABOUT REMARK 3 20% OF THE MOLECULES MAY BE FLIPPED OVER LIKE (2). THAT REMARK 3 FLIPPING WOULD PUT THE N-TERMINAL METHIONINE ON TOP OF REMARK 3 VAL 143. THUS, THE ELECTRON DENSITY MAP AT POSITION REMARK 3 VAL 143 IS MOSTLY FROM VAL 143, BUT IT ALSO CONTAINS A REMARK 3 LITTLE ELECTRON DENSITY FROM MET 1 FROM FLIPPED MOLECULES. REMARK 4 REMARK 4 1ABW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 7 REMARK 7 A NOTE FROM THE AUTHOR: REMARK 7 RESIDUES 1001-1002 AND 2001-2002 MODEL LOW OCCUPANCY REMARK 7 STRUCTURES THAT HAVE THEIR AMINO TERMINUS IN REGISTER REMARK 7 WITH VAL A143. REMARK 7 THE SPATIAL ARRANGEMENT OF TWO ALPHA CHAINS OF NORMAL REMARK 7 HEMOGLOBIN CAN BE REPRESENTED SCHEMATICALLY AS REMARK 7 GHIJ REMARK 7 F A REMARK 7 EDCB REMARK 7 WHERE FGHIJ IS ONE COVALENT CHAIN AND ABCDE THE OTHER REMARK 7 COVALENT CHAIN. REMARK 7 IN THIS MUTANT HEMOGLOBIN, THERE IS A COVALENT BOND REMARK 7 BETWEEN RESIDUE J AND A, BUT NOT BETWEEN E AND F. REMARK 7 IN THE CRYSTAL, THE AUTHORS COULD HAVE REMARK 7 GHIJ BCDE REMARK 7 F A OR A F REMARK 7 EDCB JIHG REMARK 7 (1) (2) REMARK 7 THE "F-A" CONTACT WOULD BE LIKE NORMAL HEMOGLOBIN, BUT THE REMARK 7 "E-F" CONTACT HAS A COVALENT LINKAGE THAT BREAKS THE REMARK 7 SYMMETRY. THE ONLY WAY TO TELL IF THE CRYSTAL STRUCTURE REMARK 7 IS (1) OR (2) OR A MIXTURE OF THE TWO IS TO LOOK AT THE REMARK 7 "E-F" AND "J-A" REGIONS. REMARK 7 IN THIS STRUCTURE, IT COULD BE MOSTLY (1), BUT ABOUT REMARK 7 20% OF THE MOLECULES MAY BE FLIPPED OVER LIKE (2). THAT REMARK 7 FLIPPING WOULD PUT THE N-TERMINAL METHIONINE ON TOP OF REMARK 7 VAL 143. THUS, THE ELECTRON DENSITY MAP AT POSITION REMARK 7 VAL 143 IS MOSTLY FROM VAL 143, BUT IT ALSO CONTAINS A REMARK 7 LITTLE ELECTRON DENSITY FROM MET 1 FROM FLIPPED MOLECULES. REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000170634. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : MAR-93 REMARK 200 TEMPERATURE (KELVIN) : 295 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 5 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RUH2R REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE(002) REMARK 200 OPTICS : COLLIMATOR REMARK 200 REMARK 200 DETECTOR TYPE : AREA DETECTOR REMARK 200 DETECTOR MANUFACTURER : SIEMENS REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 34054 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 82.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 77.1 REMARK 200 DATA REDUNDANCY : 2.100 REMARK 200 R MERGE (I) : 0.04600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.20 REMARK 200 COMPLETENESS FOR SHELL (%) : 56.1 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: X-PLOR 3.1 REMARK 200 STARTING MODEL: PDB ENTRY 2HHB REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 43.75 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.19 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 6.2 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 40.99000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 10590 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23440 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -111.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 HUMAN HEMOGLOBIN HAS TWO ALPHA CHAINS WHICH ARE CALLED REMARK 400 CHAINS A AND C IN OTHER PDB FILES. IN THIS ENTRY THE TWO REMARK 400 ALPHA CHAINS HAVE BEEN COVALENTLY JOINED TOGETHER BY ONE REMARK 400 GLYCINE RESIDUE TO FORM ONE COVALENTLY LINKED POLYPEPTIDE REMARK 400 CHAIN. REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 TYR A 140 N CA C O CB CG CD1 REMARK 480 TYR A 140 CD2 CE1 CE2 CZ OH REMARK 480 ARG A 141 N CA CB CG CD NE CZ REMARK 480 ARG A 141 NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH B 192 O HOH B 225 1.68 REMARK 500 O HOH A 297 O HOH A 465 1.76 REMARK 500 O HOH D 165 O HOH D 215 2.05 REMARK 500 O HOH A 333 O HOH A 423 2.15 REMARK 500 O HOH B 159 O HOH B 193 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 480 O HOH B 231 1554 0.01 REMARK 500 O HOH A 468 O HOH D 208 1556 0.05 REMARK 500 O HOH A 426 O HOH D 168 2556 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 47 N - CA - C ANGL. DEV. = -16.7 DEGREES REMARK 500 HIS B 2 CB - CA - C ANGL. DEV. = 13.5 DEGREES REMARK 500 HIS B 2 N - CA - CB ANGL. DEV. = 11.5 DEGREES REMARK 500 HIS B 2 CA - C - N ANGL. DEV. = -19.6 DEGREES REMARK 500 LEU B 3 CA - CB - CG ANGL. DEV. = 15.0 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 90 -60.49 -102.17 REMARK 500 LEU A 113 68.56 -116.64 REMARK 500 LEU A 255 74.57 -118.54 REMARK 500 HIS B 2 109.60 94.38 REMARK 500 LEU B 3 134.31 -173.38 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 HIS B 2 -20.60 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 THE RESIDUES 1001-1002 AND 2001-2002 REPRESENT LOW OCCUPANCY REMARK 600 DIPEPTIDES (MET-LEU) THAT HAVE THEIR AMINO TERMINUS IN REGISTER REMARK 600 WITH VAL A143 REMARK 615 REMARK 615 ZERO OCCUPANCY ATOM REMARK 615 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 615 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 615 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 615 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 615 M RES C SSEQI REMARK 615 LEU A 1002 REMARK 615 LEU A 2002 REMARK 615 MET A 1001 REMARK 615 MET A 2001 REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM A 284 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS A 87 NE2 REMARK 620 2 HEM A 284 NA 89.6 REMARK 620 3 HEM A 284 NB 90.3 88.4 REMARK 620 4 HEM A 284 NC 100.0 170.3 89.7 REMARK 620 5 HEM A 284 ND 97.8 88.4 171.3 92.1 REMARK 620 6 HOH A 428 O 165.7 102.6 82.7 67.7 90.0 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM A 285 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS A 229 NE2 REMARK 620 2 HEM A 285 NA 90.9 REMARK 620 3 HEM A 285 NB 87.4 87.4 REMARK 620 4 HEM A 285 NC 97.6 171.4 92.0 REMARK 620 5 HEM A 285 ND 98.6 87.6 172.2 92.0 REMARK 620 6 HOH A 466 O 171.9 92.3 85.3 79.1 88.9 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM B 147 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS B 92 NE2 REMARK 620 2 HEM B 147 NA 89.4 REMARK 620 3 HEM B 147 NB 94.7 90.5 REMARK 620 4 HEM B 147 NC 104.3 166.3 87.2 REMARK 620 5 HEM B 147 ND 96.8 89.6 168.5 90.0 REMARK 620 N 1 2 3 4 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM D 147 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS D 92 NE2 REMARK 620 2 HEM D 147 NA 95.9 REMARK 620 3 HEM D 147 NB 98.1 89.1 REMARK 620 4 HEM D 147 NC 99.1 164.9 87.1 REMARK 620 5 HEM D 147 ND 94.9 88.2 166.9 92.2 REMARK 620 N 1 2 3 4 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MET A 1001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MET A 2001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM A 284 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM A 285 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM B 147 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM D 147 REMARK 999 REMARK 999 SEQUENCE REMARK 999 GLY A 142 COVALENTLY LINKS HUMAN ALPHA CHAIN A AND C DBREF 1ABW A 143 283 UNP P69905 HBA_HUMAN 1 141 DBREF 1ABW B 2 146 UNP P68871 HBB_HUMAN 2 146 DBREF 1ABW D 2 146 UNP P68871 HBB_HUMAN 2 146 SEQADV 1ABW LYS B 108 UNP P68871 ASN 108 CONFLICT SEQADV 1ABW LYS D 108 UNP P68871 ASN 108 CONFLICT SEQRES 1 A 283 MET LEU SER PRO ALA ASP LYS THR ASN VAL LYS ALA ALA SEQRES 2 A 283 TRP GLY LYS VAL GLY ALA HIS ALA GLY GLU TYR GLY ALA SEQRES 3 A 283 GLU ALA LEU GLU ARG MET PHE LEU SER PHE PRO THR THR SEQRES 4 A 283 LYS THR TYR PHE PRO HIS PHE ASP LEU SER HIS GLY SER SEQRES 5 A 283 ALA GLN VAL LYS GLY HIS GLY LYS LYS VAL ALA ASP ALA SEQRES 6 A 283 LEU THR ASN ALA VAL ALA HIS VAL ASP ASP MET PRO ASN SEQRES 7 A 283 ALA LEU SER ALA LEU SER ASP LEU HIS ALA HIS LYS LEU SEQRES 8 A 283 ARG VAL ASP PRO VAL ASN PHE LYS LEU LEU SER HIS CYS SEQRES 9 A 283 LEU LEU VAL THR LEU ALA ALA HIS LEU PRO ALA GLU PHE SEQRES 10 A 283 THR PRO ALA VAL HIS ALA SER LEU ASP LYS PHE LEU ALA SEQRES 11 A 283 SER VAL SER THR VAL LEU THR SER LYS TYR ARG GLY VAL SEQRES 12 A 283 LEU SER PRO ALA ASP LYS THR ASN VAL LYS ALA ALA TRP SEQRES 13 A 283 GLY LYS VAL GLY ALA HIS ALA GLY GLU TYR GLY ALA GLU SEQRES 14 A 283 ALA LEU GLU ARG MET PHE LEU SER PHE PRO THR THR LYS SEQRES 15 A 283 THR TYR PHE PRO HIS PHE ASP LEU SER HIS GLY SER ALA SEQRES 16 A 283 GLN VAL LYS GLY HIS GLY LYS LYS VAL ALA ASP ALA LEU SEQRES 17 A 283 THR ASN ALA VAL ALA HIS VAL ASP ASP MET PRO ASN ALA SEQRES 18 A 283 LEU SER ALA LEU SER ASP LEU HIS ALA HIS LYS LEU ARG SEQRES 19 A 283 VAL ASP PRO VAL ASN PHE LYS LEU LEU SER HIS CYS LEU SEQRES 20 A 283 LEU VAL THR LEU ALA ALA HIS LEU PRO ALA GLU PHE THR SEQRES 21 A 283 PRO ALA VAL HIS ALA SER LEU ASP LYS PHE LEU ALA SER SEQRES 22 A 283 VAL SER THR VAL LEU THR SER LYS TYR ARG SEQRES 1 B 146 MET HIS LEU THR PRO GLU GLU LYS SER ALA VAL THR ALA SEQRES 2 B 146 LEU TRP GLY LYS VAL ASN VAL ASP GLU VAL GLY GLY GLU SEQRES 3 B 146 ALA LEU GLY ARG LEU LEU VAL VAL TYR PRO TRP THR GLN SEQRES 4 B 146 ARG PHE PHE GLU SER PHE GLY ASP LEU SER THR PRO ASP SEQRES 5 B 146 ALA VAL MET GLY ASN PRO LYS VAL LYS ALA HIS GLY LYS SEQRES 6 B 146 LYS VAL LEU GLY ALA PHE SER ASP GLY LEU ALA HIS LEU SEQRES 7 B 146 ASP ASN LEU LYS GLY THR PHE ALA THR LEU SER GLU LEU SEQRES 8 B 146 HIS CYS ASP LYS LEU HIS VAL ASP PRO GLU ASN PHE ARG SEQRES 9 B 146 LEU LEU GLY LYS VAL LEU VAL CYS VAL LEU ALA HIS HIS SEQRES 10 B 146 PHE GLY LYS GLU PHE THR PRO PRO VAL GLN ALA ALA TYR SEQRES 11 B 146 GLN LYS VAL VAL ALA GLY VAL ALA ASN ALA LEU ALA HIS SEQRES 12 B 146 LYS TYR HIS SEQRES 1 D 146 MET HIS LEU THR PRO GLU GLU LYS SER ALA VAL THR ALA SEQRES 2 D 146 LEU TRP GLY LYS VAL ASN VAL ASP GLU VAL GLY GLY GLU SEQRES 3 D 146 ALA LEU GLY ARG LEU LEU VAL VAL TYR PRO TRP THR GLN SEQRES 4 D 146 ARG PHE PHE GLU SER PHE GLY ASP LEU SER THR PRO ASP SEQRES 5 D 146 ALA VAL MET GLY ASN PRO LYS VAL LYS ALA HIS GLY LYS SEQRES 6 D 146 LYS VAL LEU GLY ALA PHE SER ASP GLY LEU ALA HIS LEU SEQRES 7 D 146 ASP ASN LEU LYS GLY THR PHE ALA THR LEU SER GLU LEU SEQRES 8 D 146 HIS CYS ASP LYS LEU HIS VAL ASP PRO GLU ASN PHE ARG SEQRES 9 D 146 LEU LEU GLY LYS VAL LEU VAL CYS VAL LEU ALA HIS HIS SEQRES 10 D 146 PHE GLY LYS GLU PHE THR PRO PRO VAL GLN ALA ALA TYR SEQRES 11 D 146 GLN LYS VAL VAL ALA GLY VAL ALA ASN ALA LEU ALA HIS SEQRES 12 D 146 LYS TYR HIS HET MET A1001 8 HET LEU A1002 9 HET MET A2001 8 HET LEU A2002 9 HET HEM A 284 43 HET HEM A 285 43 HET HEM B 147 43 HET HEM D 147 43 HETNAM MET METHIONINE HETNAM LEU LEUCINE HETNAM HEM PROTOPORPHYRIN IX CONTAINING FE HETSYN HEM HEME FORMUL 4 MET 2(C5 H11 N O2 S) FORMUL 5 LEU 2(C6 H13 N O2) FORMUL 8 HEM 4(C34 H32 FE N4 O4) FORMUL 12 HOH *373(H2 O) HELIX 1 1 PRO A 4 SER A 35 1 32 HELIX 2 2 PRO A 37 TYR A 42 5 6 HELIX 3 3 ALA A 53 ALA A 71 1 19 HELIX 4 4 VAL A 73 ALA A 79 5 7 HELIX 5 5 SER A 81 HIS A 89 1 9 HELIX 6 6 PRO A 95 HIS A 112 5 18 HELIX 7 7 PRO A 119 THR A 137 1 19 HELIX 8 8 PRO A 146 SER A 177 1 32 HELIX 9 9 PRO A 179 TYR A 184 5 6 HELIX 10 10 ALA A 195 ALA A 213 1 19 HELIX 11 11 MET A 218 ALA A 221 1 4 HELIX 12 12 SER A 223 HIS A 231 1 9 HELIX 13 13 PRO A 237 HIS A 254 5 18 HELIX 14 14 PRO A 261 LEU A 278 1 18 HELIX 15 15 PRO B 5 LYS B 17 1 13 HELIX 16 16 VAL B 20 VAL B 34 1 15 HELIX 17 17 PRO B 36 PHE B 41 5 6 HELIX 18 18 GLU B 43 PHE B 45 5 3 HELIX 19 19 PRO B 51 GLY B 56 1 6 HELIX 20 20 PRO B 58 HIS B 77 1 20 HELIX 21 21 LEU B 81 ASP B 94 1 14 HELIX 22 22 PRO B 100 HIS B 116 5 17 HELIX 23 23 GLY B 119 GLU B 121 5 3 HELIX 24 24 PRO B 124 ALA B 142 1 19 HELIX 25 25 PRO D 5 LYS D 17 1 13 HELIX 26 26 VAL D 20 VAL D 34 1 15 HELIX 27 27 PRO D 36 PHE D 41 5 6 HELIX 28 28 GLU D 43 PHE D 45 5 3 HELIX 29 29 PRO D 51 GLY D 56 1 6 HELIX 30 30 PRO D 58 HIS D 77 1 20 HELIX 31 31 LEU D 81 ASP D 94 1 14 HELIX 32 32 PRO D 100 GLU D 121 5 22 HELIX 33 33 PRO D 124 ALA D 142 1 19 LINK C BMET A1001 N BLEU A1002 1555 1555 1.33 LINK C CMET A2001 N CLEU A2002 1555 1555 1.33 LINK NE2 HIS A 87 FE HEM A 284 1555 1555 2.33 LINK NE2 HIS A 229 FE HEM A 285 1555 1555 2.16 LINK FE HEM A 284 O HOH A 428 1555 1555 2.82 LINK FE HEM A 285 O HOH A 466 1555 1555 2.54 LINK NE2 HIS B 92 FE HEM B 147 1555 1555 2.16 LINK NE2 HIS D 92 FE HEM D 147 1555 1555 2.13 SITE 1 AC1 7 GLY A 142 VAL A 143 LEU A 144 LYS A 269 SITE 2 AC1 7 ALA A 272 SER A 273 MET A2001 SITE 1 AC2 4 GLY A 142 VAL A 143 LEU A 144 MET A1001 SITE 1 AC3 16 TYR A 42 PHE A 43 HIS A 45 HIS A 58 SITE 2 AC3 16 LYS A 61 LEU A 83 HIS A 87 LEU A 91 SITE 3 AC3 16 VAL A 93 ASN A 97 PHE A 98 LEU A 101 SITE 4 AC3 16 LEU A 136 HOH A 320 HOH A 428 HOH A 431 SITE 1 AC4 16 TYR A 184 PHE A 185 HIS A 187 HIS A 200 SITE 2 AC4 16 LYS A 203 LEU A 225 LEU A 228 HIS A 229 SITE 3 AC4 16 LEU A 233 VAL A 235 ASN A 239 PHE A 240 SITE 4 AC4 16 LEU A 243 LEU A 278 HOH A 327 HOH A 466 SITE 1 AC5 15 SER A 52 ALA A 53 HOH A 389 PHE B 41 SITE 2 AC5 15 HIS B 63 VAL B 67 ALA B 70 LEU B 91 SITE 3 AC5 15 HIS B 92 LEU B 96 ASN B 102 PHE B 103 SITE 4 AC5 15 LEU B 106 LEU B 141 HOH B 169 SITE 1 AC6 11 PHE D 41 HIS D 63 VAL D 67 LEU D 91 SITE 2 AC6 11 HIS D 92 LEU D 96 VAL D 98 ASN D 102 SITE 3 AC6 11 PHE D 103 LEU D 106 LEU D 141 CRYST1 62.900 81.980 53.920 90.00 98.99 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015898 0.000000 0.002515 0.00000 SCALE2 0.000000 0.012198 0.000000 0.00000 SCALE3 0.000000 0.000000 0.018777 0.00000